Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Roland Buhl, Dave Singh, Alberto De La Hoz, Florian Voß, Gary T. Ferguson
European Respiratory Journal 2019 54: PA3382; DOI: 10.1183/13993003.congress-2019.PA3382
Roland Buhl
1Johannes Gutenberg University Hospital Mainz, Mainz, Germany
Dave Singh
2Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Alberto De La Hoz
3Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
Florian Voß
4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Gary T. Ferguson
5Pulmonary Research Institute of Southeast Michigan, Farmington Hills, United States of America
Vol 54 Issue suppl 63
Table of Contents
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Roland Buhl, Dave Singh, Alberto De La Hoz, Florian Voß, Gary T. Ferguson
European Respiratory Journal Sep 2019, 54 (suppl 63) PA3382; DOI: 10.1183/13993003.congress-2019.PA3382
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Roland Buhl, Dave Singh, Alberto De La Hoz, Florian Voß, Gary T. Ferguson
European Respiratory Journal Sep 2019, 54 (suppl 63) PA3382; DOI: 10.1183/13993003.congress-2019.PA3382